Abstract
Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease- modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Keywords: Alzheimer’s disease, neurodegeneration, drug repositioning, tau protein, amyloid-β peptide, pharmacophores.
Current Alzheimer Research
Title:Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives
Volume: 15 Issue: 12
Author(s): Alexandre A. de Castro, Elaine F.F. da Cunha, Ander F. Pereira, Flavia V. Soares, Daniel H.S. Leal, Kamil Kuca and Teodorico C. Ramalho*
Affiliation:
- Department of Chemistry, Federal University of Lavras, Lavras/MG, 37200-000,Brazil
Keywords: Alzheimer’s disease, neurodegeneration, drug repositioning, tau protein, amyloid-β peptide, pharmacophores.
Abstract: Introduction: Alzheimer's disease is known to be a chronic disease, with an estimated prevalence of about 10-30%, considering the population over 60 years of age. Most patients with this disorder (> 95%) present the sporadic form, being characterized by a late onset (80-90 years of age), and it is the consequence of the failure to clear the amyloid-β (Aβ) peptide from the interstices of the brain. Significant numbers of genetic risk factors for the sporadic disease have been researched. Some existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease- modifying therapies. In this line, a complementary strategy based on repositioning drugs which are approved for the treatment of other disorders could be interesting. It is noteworthy the fact that some clinical trials indicate that several classes of drugs own potent and beneficial effects on the Alzheimer's disease treatment. In this present work, we present the details and evaluation of these alternative treatments. It has highlighted several compounds with relevant evidence for this purpose, which deserves further investigation to clarify optimal treatment conditions in the clinical trials of patients with Alzheimer's disease.
Export Options
About this article
Cite this article as:
de Castro A. Alexandre, da Cunha F.F. Elaine , Pereira F. Ander , Soares V. Flavia, Leal H.S. Daniel , Kuca Kamil and Ramalho C. Teodorico *, Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives, Current Alzheimer Research 2018; 15 (12) . https://dx.doi.org/10.2174/1567205015666180813150703
DOI https://dx.doi.org/10.2174/1567205015666180813150703 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet the Editorial Board
CNS & Neurological Disorders - Drug Targets Treatment of Acute Hypercalcemia
Medicinal Chemistry Vasopressin Secretion Control: Central Neural Pathways, Neurotransmitters and Effects of Drugs
Current Pharmaceutical Design Ester Prodrugs of Ketoprofen: Synthesis, In Vitro Stability, In Vivo Biological Evaluation and In Silico Comparative Docking Studies Against COX-1 and COX-2
Current Drug Discovery Technologies Mechanisms of HIV Transcriptional Regulation by Drugs of Abuse
Current HIV Research Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis
Current Medicinal Chemistry Marine Natural Products with Anti-HIV Activities in the Last Decade
Current Medicinal Chemistry New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery Hereditary Parkinsonism-Associated Genetic Variations in PARK9 Locus Lead to Functional Impairment of ATPase Type 13A2
Current Protein & Peptide Science Sexual and Gender-Based Violence Attitudes and Experiences among Nine Sub-Saharan African Militaries
Current HIV Research Antibody Responses, Amyloid-β Peptide Remnants and Clinical Effects of AN-1792 Immunization in Patients with AD in an Interrupted Trial
CNS & Neurological Disorders - Drug Targets Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Plant Ribonucleases and Nucleases as Antiproliferative Agens Targeting Human Tumors Growing in Mice
Recent Patents on DNA & Gene Sequences Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder
CNS & Neurological Disorders - Drug Targets Cost of Treatment and Care for People with Alzheimer’s Disease: A Meta- Analysis
Current Alzheimer Research Targeting the Toll of Drug Abuse: The Translational Potential of Toll-Like Receptor 4
CNS & Neurological Disorders - Drug Targets Stem Cell Therapy for the Treatment of Myocardial Infarction
Current Pharmaceutical Design Identify Golgi Protein Types with Modified Mahalanobis Discriminant Algorithm and Pseudo Amino Acid Composition
Protein & Peptide Letters Current Opioid Overdose Crisis: Some Comments on the Chemicobiological Aspects of Tolerance/Dependence and Abuse Based on Computational Chemistry and Biology
Current Computer-Aided Drug Design Novel Aβ Immunogens: Is Shorter Better?
Current Alzheimer Research